Immunovant (IMVT)
(Delayed Data from NSDQ)
$30.92 USD
+0.41 (1.34%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $30.92 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Immunovant, Inc. [IMVT]
Reports for Purchase
Showing records 81 - 100 ( 105 total )
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
LDL Signal Manageable and Clinical Trials to Restart; Though Questions Still Remian
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Safety Rules: We Upgrade argenx as Survey Points to Market Leadership for Efgartigimod
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Down But Not Out: Our Revised View of IMVT-1401?s Adoption; Reit Buy, PT Down to $23
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways From Our Coverage at the American Academy of Neurology 2021 Virtual Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Additional Nipocalimab Data Doesn?t Offer Clarity on Albumin Levels or Potential Cholesterol Changes
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Immunovant Reports F3Q21 Earnings With No Update on Paused Studies; Reiterate Buy, Maintain PT at $33
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Trials Put on Hold as LDL Signal Identified; Reiterate Buy Though Lower Price Target to $33
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
wAIHA and TED Studies Delayed by One Quarter due to COVID-19 Surge; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Setting-up SC IMVT-1401 for the Broader Anti- FcRn Space; Reiterate Buy, Raise Price Target to $54
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Pharmaceuticals/Specialty - Expert Call: An Update on the Tepezza Launch
Provider: Jefferies & Company
Analyst: Research Department